Dbv Technologies
France corporation · 1 known investors
DBV Technologies is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy treatments, primarily the VIASKIN patch, for food allergies and immunological diseases. The company focuses on treating peanut allergy, cow's milk allergy, and related conditions in pediatric and adult patients.
Founders & leadership
PM
Pharis MohideenExecutive
DT
Daniel TasseExecutive
VB
Virginie BoucinhaExecutive
Board
MF
Mailys FerrereBoard director
MG
Michael GollerBoard director
RM
Ravi Madduri RaoBoard director
DG
Daniele Guyot-CaparrosBoard director
DS
Daniel SolandBoard director
AN
Adora NduBoard director
JO
Julie O'NeillBoard director
MD
Michel de RosenBoard director
TE
Timothy E. MorrisBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$306.9M disclosed across 1 round · 2025
▶$306.9MraisedApr 2025 · 14 investors · PharmaceuticalsRule 506(b)
▶$306.9MraisedApr 2025 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mailys FerrereDirector
- Ravi Madduri RaoDirector
- Daniele Guyot-CaparrosDirector
- Pharis MohideenExecutive Officer
- Daniel SolandDirector
- Adora NduDirector
- Julie O'NeillDirector
- Daniel TasseExecutive Officer, Director
- Virginie BoucinhaExecutive Officer
- Michel de RosenDirector
- Timothy E. MorrisDirector
- Michael GollerDirector
- Offering amount
- $306.9M
- Amount sold
- $306.9M
- Sales commissions
- $18.4M
- Placement agents
- Van Lanschot Kempen NV, Van Lanschot Kempen (USA) Inc., LifeSci Capital LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, France
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
TradingView24 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking Alpha18 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Public16 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies competing with Dbv Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Dbv Technologies do?
- DBV Technologies is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy treatments, primarily the VIASKIN patch, for food allergies and immunological diseases. The company focuses on treating peanut allergy, cow's milk allergy, and related conditions in pediatric and adult patients.
- Who are Dbv Technologies's investors?
- Dbv Technologies's investors include Karista.
- How much funding has Dbv Technologies raised?
- Dbv Technologies has disclosed $306.9M raised across 1 round.